Abstract
Adoptive transfer of T cells with restricted tumor specificity provides a promising approach to immunotherapy of cancers. However, the isolation of autologous cytotoxic T cells that recognize tumor-associated antigens is time consuming and fails in many instances. Alternatively, gene modification with tumor antigen-specific T-cell receptors (TCR) or chimeric antigen receptors (CARs) can be used to redirect the specificity of large numbers of immune cells toward the malignant cells. Chimeric antigen receptors are composed of the single-chain variable fragment (scFv) of a tumor-recognizing antibody cloned in frame with human T-cell signaling domains (e.g., CD3ζ, CD28, OX40, 4-1BB), thus combining the specificity of antibodies with the effector functions of cytotoxic T cells. Upon antigen binding, the intracellular signaling domains of the CAR initiate cellular activation mechanisms including cytokine secretion and cytolysis of the antigen-positive target cell.
In this chapter, we provide detailed protocols for large-scale ex vivo expansion of T cells and manufacturing of medium-scale batches of CAR-expressing T cells for translational research by mRNA electroporation. An anti-CD19 chimeric receptor for the targeting of leukemias and lymphomas was used as a model system. We are currently scaling up the protocols to adapt them to cGMP production of a large number of redirected T cells for clinical applications
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
June, C.H. (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest, 117(6), 1466–1476.
Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A. et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23(10), 2346–2357.
Leen, A.M., Rooney, C.M., and Foster, A.E. (2007) Improving T cell therapy for cancer. Annu Rev Immunol, 25, 243–265.
Porter, D.L. and Antin, J.H. (2006) Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol, 19(4), 737–755.
Rosenberg, S.A. and Dudley, M.E. (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA, 101(Suppl 2), 14639–14645.
Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.E. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer, 8(4), 299–308.
Yee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Celis, E., and Greenberg, P.D. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA, 99(25), 16168–16173.
June, C.H. (2007) Principles of adoptive T cell cancer therapy. J Clin Invest, 117(5), 1204–1212.
Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliott, C., and Riddell, S.R. (2007) Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest, 118(1), 294–305.
Perret, R. and Ronchese, F. (2008) Memory T cells in cancer immunotherapy: which CD8(+) T-cell population provides the best protection against tumours? Tissue Antigens, 72(3), 187–194.
de Visser, K.E., Schumacher, T.N., and Kruisbeek, A.M. (2003) CD8+ T cell tolerance and cancer immunotherapy. J Immunother (1997), 26(1), 1–11.
Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol, 6(5), 383–393.
Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P. et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126–129.
Cooper, L.J., Al-Kadhimi, Z., DiGiusto, D., Kalos, M., Colcher, D., Raubitschek, A., Forman, S.J., and Jensen, M.C. (2004) Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis, 33(1), 83–89.
Eshhar, Z. (2008) The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol, 181, 329–342.
Emtage, P.C.R., Lo, A.S.Y., Gomes, E.M., Liu, D.L., Gonzalo-Daganzo, R.M., and Junghans, R.P. (2008) Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res, 14, 8112–8122.
Yu, K., Hu, Y., Tan, Y., Shen, Z., Jiang, S., Qian, H., Liang, B., and Shan, D. (2008) Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma, 49(7), 1368–1373.
Sadelain, M., Riviere, I., and Brentjens, R. (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer, 3(1), 35–45.
Aptsiauri, N., Cabrera, T., Garcia-Lora, A., Lopez-Nevot, M.A., Ruiz-Cabello, F., and Garrido, F. (2007) MHC Class I antigens and immune surveillance in transformed cells. In: Kwang, W.J. (Ed.) International Review of Cytology a Survey of Cell Biology. Academic Press, New York, pp. 139–189.
Engels, B. and Uckert, W. (2007) Redirecting T lymphocyte specificity by T cell receptor gene transfer – a new era for immunotherapy. Mol Aspects Med, 28(1), 115–142.
Uckert, W. and Schumacher, T.N. (2009) TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother, 58(5), 809–822.
Mezzanzanica, D., Canevari, S., Mazzoni, A., Figini, M., Colnaghi, M.I., Waks, T., Schindler, D.G., and Eshhar, Z. (1998) Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther, 5(6), 401–407.
Krause, A., Guo, H.F., Latouche, J.B., Tan, C., Cheung, N.K., and Sadelain, M. (1998) Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med, 188(4), 619–626.
Yun, C.O., Nolan, K.F., Beecham, E.J., Reisfeld, R.A., and Junghans, R.P. (2000) Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia, 2(5), 449–459.
Westwood, J.A., Murray, W.K., Trivett, M., Haynes, N.M., Solomon, B., Mileshkin, L., Ball, D., Michael, M., Burman, A., Mayura-Guru, P. et al. (2009) The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother, 32(3), 292–301.
Kennedy, R. and Celis, E. (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev, 222, 129–144.
Elinav, E., Waks, T., and Eshhar, Z. (2008) Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology, 134(7), 2014–2024.
Eran, E., Nitzan, A., Tova, W., and Eshhar, Z. (2009) Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology, 136(5), 1721–1731.
Boissel, L., Betancur, M., Wels, W.S., Tuncer, H., and Klingemann, H. (2009) Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leukemia Res, 33(9), 1255–1259.
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.G., and Wels, W. (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood, 100(4), 1265–1273.
Muller, T., Uherek, C., Maki, G., Chow, K.U., Schimpf, A., Klingemann, H.G., Tonn, T., and Wels, W.S. (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother, 57(3), 411–423.
Rischer, M., Pscherer, S., Duwe, S., Vormoor, J., Jurgens, H., and Rossig, C. (2004) Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol, 126(4), 583–592.
Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA, 90(2), 720–724.
Hombach, A. and Abken, H. (2007) Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother, 56(5), 731–737.
Finney, H.M., Lawson, A.D., Bebbington, C.R., and Weir, A.N. (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol, 161(6), 2791–2797.
Pule, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M., and Brenner, M.K. (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther, 12(5), 933–941.
Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M. et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA, 106(9), 3360–3365.
Finney, H.M., Akbar, A.N., and Lawson, A.D. (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol, 172(1), 104–113.
Cotrim, A.P. and Baum, B.J. (2008) Gene therapy: some history, applications, problems, and prospects. Toxicol Pathol, 36, 97–103.
Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K. et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 118(9), 3132–3142.
Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kuhlcke, K., Schilz, A., Kunkel, H. et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 12, 401–409.
Hege, K.M. and Roberts, M.R. (1996) T-cell gene therapy. Curr Opin Biotechnol, 7(6), 629–634.
Muul, L.M., Tuschong, L.M., Soenen, S.L., Jagadeesh, G.J., Ramsey, W.J., Long, Z., Carter, C.S., Garabedian, E.K., Alleyne, M., Brown, M. et al. (2003) Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood, 101, 2563–2569.
Muul, L.M. and Candotti, F. (2007) Immune responses to gene-modified T cells. Curr Gene Ther, 7(5), 361–368.
Newrzela, S., Cornils, K., Li, Z., Baum, C., Brugman, M.H., Hartmann, M., Meyer, J., Hartmann, S., Hansmann, M.L., Fehse, B. et al. (2008) Resistance of mature T cells to oncogene transformation. Blood, 112, 2278–2286.
Westwood, J.A., Murray, W.K., Trivett, M., Shin, A., Neeson, P., Macgregor, D.P., Haynes, N.M., Trapani, J.A., Mayura-Guru, P., Fox, S. et al. (2008) Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther, 15, 1056–1066.
Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol, 24(13), e20–e22.
Bonini, C., Bondanza, A., Perna, S.K., Kaneko, S., Traversari, C., Ciceri, F., and Bordignon, C. (2007) The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther, 15(7), 1248–1252.
Sullenger, B.A. and Gilboa, E. (2002) Emerging clinical applications of RNA. Nature, 418, 252–258.
Gilboa, E. and Vieweg, J. (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev, 199, 251–263.
Kyte, J.A. and Gaudernack, G. (2006) Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother, 55(11), 1432–1442.
Zhao, Y., Zheng, Z., Cohen, C.J., Gattinoni, L., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A. (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther, 13(1), 151–159.
Rabinovich, P.M., Komarovskaya, M.E., Ye, Z.J., Imai, C., Campana, D., Bahceci, E., and Weissman, S.M. (2006) Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther, 17(10), 1027–1035.
Yoon, S.H., Lee, J.M., Cho, H.I., Kim, E.K., Kim, H.S., Park, M.Y., and Kim, T.G. (2008) Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2//neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther, 16, 489–497.
Birkholz, K., Hombach, A., Krug, C., Reuter, S., Kershaw, M., Kampgen, E., Schuler, G., Abken, H., Schaft, N., and Dorrie, J. (2009) Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther, 16, 596–604.
Robbins, P.F., Dudley, M.E., Wunderlich, J., El-Gamil, M., Li, Y.F., Zhou, J., Huang, J., Powell, D.J., Jr., and Rosenberg, S.A. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol, 173(12), 7125–7130.
Mitchell, D.A., Karikari, I., Cui, X., Xie, W., Schmittling, R., and Sampson, J.H. (2008) Selective modification of antigen-specific T cells by RNA electroporation. Hum Gene Ther, 19(5), 511–521.
Kershaw, M.H., Wang, G., Westwood, J.A., Pachynski, R.K., Tiffany, H.L., Marincola, F.M., Wang, E., Young, H.A., Murphy, P.M., and Hwu, P. (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther, 13(16), 1971–1980.
Yin, J., Ma, Z., Selliah, N., Shivers, D.K., Cron, R.Q., and Finkel, T.H. (2006) Effective gene suppression using small interfering RNA in hard-to-transfect human T cells. J Immunol Methods, 312(1–2), 1–11.
Mantei, A., Rutz, S., Janke, M., Kirchhoff, D., Jung, U., Patzel, V., Vogel, U., Rudel, T., Andreou, I., Weber, M. et al. (2008) siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur J Immunol, 38(9), 2616–2625.
Thomas, D.A. and Massagu, J. (2005) TGF-[beta] directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 8, 369–380.
Walczak, P., Ruiz-Cabello, J., Kedziorek, D.A., Gilad, A.A., Lin, S., Barnett, B., Qin, L., Levitsky, H., and Bulte, J.W.M. (2006) Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent. Nanomed Nanotechnol Biol Med, 2, 89–94.
Long, C.M. and Bulte, J.W. (2009) In vivo tracking of cellular therapeutics using magnetic resonance imaging. Expert Opin Biol Ther, 9(3), 293–306.
drup-Link, H.E., Meier, R., Rudelius, M., Piontek, G., Piert, M., Metz, S., Settles, M., Uherek, C., Wels, W., Schlegel, J. et al. (2005) In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol, 15(1), 4–13.
CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia. (NCT00586391). 2008. Baylor College of Medicine. Ref Type: Case
Roger Williams Medical Center. Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer after Non-Myeloablative Conditioning. ClinicalTrials.gov. 2008. Ref Type: Electronic Citation
Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A. et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 319(25), 1676–1680.
Levine, B.L., Cotte, J., Small, C.C., Carroll, R.G., Riley, J.L., Bernstein, W.B., Van Epps, D.E., Hardwick, R.A., and June, C.H. (1998) Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother, 7(5), 437–448.
Levine, B.L., Mosca, J.D., Riley, J.L., Carroll, R.G., Vahey, M.T., Jagodzinski, L.L., Wagner, K.F., Mayers, D.L., Burke, D.S., Weislow, O.S. et al. (1996) Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science, 272(5270), 1939–1943.
Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson, C.B., and June, C.H. (1997) Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol, 159, 5921–5930.
Bonyhadi, M., Frohlich, M., Rasmussen, A., Ferrand, C., Grosmaire, L., Robinet, E., Leis, J., Maziarz, R.T., Tiberghien, P., and Berenson, R.J. (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol, 174(4), 2366–2375.
Garlie, N.K., LeFever, A.V., Siebenlist, R.E., Levine, B.L., June, C.H., and Lum, L.G. (1999) T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother, 22(4), 336–345.
Porter, D.L., Levine, B.L., Bunin, N., Stadtmauer, E.A., Luger, S.M., Goldstein, S., Loren, A., Phillips, J., Nasta, S., Perl, A. et al. (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood, 107(4), 1325–1331.
Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J., and Frohlich, M.W. (2003) A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res, 9(10 Pt 1), 3562–3570.
Hami, L.S., Green, C., Leshinsky, N., Markham, E., Miller, K., and Craig, S. (2004) GMP production and testing of Xcellerated T cells for the treatment of patients with CLL. Cytotherapy, 6(6), 554–562.
Kalamasz, D., Long, S.A., Taniguchi, R., Buckner, J.H., Berenson, R.J., and Bonyhadi, M. (2004) Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J Immunother (1997), 27(5), 405–418.
Hami, L.S., Harjinder, C., Yan, V., and Craig, S. (2003) Comparison of a static process and the bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing J, 2, 1–10.
Berger, C., Blau, C.A., Clackson, T., Riddell, S.R., and Heimfeld, S. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood, 101, 476–484.
Levine, B.L., Bernstein, W.B., Aronson, N.E., Schlienger, K., Cotte, J., Perfetto, S., Humphries, M.J., Ratto-Kim, S., Birx, D.L., Steffens, C. et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med, 8(1), 47–53.
Laport, G.G., Levine, B.L., Stadtmauer, E.A., Schuster, S.J., Luger, S.M., Grupp, S., Bunin, N., Strobl, F.J., Cotte, J., Zheng, Z. et al. (2003) Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood, 102(6), 2004–2013.
Rapoport, A.P., Levine, B.L., Badros, A., Meisenberg, B., Ruehle, K., Nandi, A., Rollins, S., Natt, S., Ratterree, B., Westphal, S. et al. (2004) Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant, 33(1), 53–60.
Paulos, C.M., Suhoski, M.M., Plesa, G., Jiang, T., Basu, S., Golovina, T.N., Jiang, S., Aqui, N.A., Powell, D.J., Jr., Levine, B.L. et al. (2008) Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res, 42(1–3), 182–196.
Mitsuyasu, R.T., Anton, P.A., Deeks, S.G., Scadden, D.T., Connick, E., Downs, M.T., Bakker, A., Roberts, M.R., June, C.H., Jalali, S. et al. (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood, 96(3), 785–793.
Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J., and Frohlich, M.W. (2003) A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res, 9(10 Pt 1), 3562–3570.
Rapoport, A.P., Stadtmauer, E.A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R. et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med, 11(11), 1230–1237.
Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z. et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med, 14, 1264–1270.
Rosenberg, S.A., Yang, J.C., Robbins, P.F., Wunderlich, J.R., Hwu, P., Sherry, R.M., Schwartzentruber, D.J., Topalian, S.L., Restifo, N.P., Filie, A. et al. (2003) Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (1997), 26(5), 385–393.
de Goer de Herve, M.-G., Cariou, A., Simonetta, F., and Taoufik, Y. (2008) Heterospecific CD4 help to rescue CD8 T cell killers. J Immunol, 181, 5974–5980.
Rasmussen, A.M. et al. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. (submitted).
Butterfield, L.H., Ribas, A., Dissette, V.B., Amarnani, S.N., Vu, H.T., Oseguera, D., Wang, H.J., Elashoff, R.M., McBride, W.H., Mukherji, B. et al. (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res, 9(3), 998–1008.
Wada, J., Yamasaki, A., Nagai, S., Yanai, K., Fuchino, K., Kameda, C., Tanaka, H., Koga, K., Nakashima, H., Nakamura, M. et al. (2008) Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients. Anticancer Res, 28(4C), 2401–2408.
Curiel, T.J. (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol, 20(2), 241–246.
Griffiths, R.W., Elkord, E., Gilham, D.E., Ramani, V., Clarke, N., Stern, P.L., and Hawkins, R.E. (2007) Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother, 56(11), 1743–1753.
Wolf, A.M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., and Grubeck-Loebenstein, B. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res, 9(2), 606–612.
Dudley, M.E., Wunderlich, J.R., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R.M., Marincola, F.M., Leitman, S.F., Seipp, C.A. et al. (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (1997), 25(3), 243–251.
Dannull, J., Su, Z., Rizzieri, D., Yang, B.K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E. et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 115(12), 3623–3633.
Thistlethwaite, F.C., Elkord, E., Griffiths, R.W., Burt, D.J., Shablak, A.M., Campbell, J.D., Gilham, D.E., Austin, E.B., Stern, P.L., and Hawkins, R.E. (2008) Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother, 57(5), 623–634.
Mahnke, K., Schonfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T., Johnson, T.S., Storn, V., Schallenberg, S. et al. (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer, 120(12), 2723–2733.
Cheadle, E.J., Hawkins, R.E., Batha, H., Rothwell, D.G., Ashton, G., and Gilham, D.E. (2009) Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother, 32(3), 207–218.
Neurauter, A.A., Bonyhadi, M., Lien, E., Nokleby, L., Ruud, E., Camacho, S., and Aarvak, T. (2008) Cell isolation and expansion using dynabeads (r). Adv Biochem Eng Biotechnol, 106, 41–73.
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J. et al. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother, 32(2), 169–180.
Saeboe-Larssen, S., Fossberg, E., and Gaudernack, G. (2002) mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods, 259(1–2), 191–203.
Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., and Koup, R.A. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods, 281(1–2), 65–78.
Mittendorf, E.A., Storrer, C.E., Shriver, C.D., Ponniah, S., and Peoples, G.E. (2005) Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat, 92(1), 85–93.
Disis, M.L., Dela, R.C., Goodell, V., Kuan, L.Y., Chang, J.C., Kuus-Reichel, K., Clay, T.M., Kim, L.H., Bhatia, S., Ghanekar, S.A. et al. (2006) Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods, 308(1–2), 13–18.
Smits, E., Ponsaerts, P., Lenjou, M., Nijs, G., Van Bockstaele, D.R., Berneman, Z.N., and Van, T.V. (2004) RNA-based gene transfer for adult stem cells and T cells. Leukemia, 18(11), 1898–1902.
Schaft, N., Dorrie, J., Muller, I., Beck, V., Baumann, S., Schunder, T., Kampgen, E., and Schuler, G. (2006) A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother, 55(9), 1132–1141.
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Tureci, O., and Sahin, U. (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 108, 4009–4017.
Pasquinelli, A.E., Dahlberg, J.E., and Lund, E. (1995) Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA, 1(9), 957–967.
Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E., and Rhoads, R.E. (2001) Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA, 7(10), 1486–1495.
Tan, X. and Wan, Y. (2008) Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Hum Immunol, 69(1), 32–40.
Liu, Y. and Bergan, R. (2001) Improved intracellular delivery of oligonucleotides by square wave electroporation. Antisense Nucleic Acid Drug Dev, 11, 7–14.
Almåsbak, H. et al. Transiently redirected T cells for adoptive transfer: coelectroporation of chimeric antigen and chemokine receptor mRNAs. (in preparation).
Acknowledgments
This work was supported in part by CHILDHOPE (EU contract #037381) and the authors would like to thank Dr. Martin Pulè at UCL Cancer Institute, University College London, UK, for providing the vector for the chimeric antigen receptor. The authors would also thank Dr. Stein Sæebøe-Larssen at our laboratory for providing the pCIpA102 expression vector and Dr. Rainer Loew at EUFETS, Idar-Oberstein, Germany, for the IRES-EGFP construct.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Almåsbak, H., Lundby, M., Rasmussen, AM. (2010). Non-MHC-Dependent Redirected T Cells Against Tumor Cells. In: Sioud, M. (eds) RNA Therapeutics. Methods in Molecular Biology, vol 629. Humana Press. https://doi.org/10.1007/978-1-60761-657-3_28
Download citation
DOI: https://doi.org/10.1007/978-1-60761-657-3_28
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-656-6
Online ISBN: 978-1-60761-657-3
eBook Packages: Springer Protocols